Nephros (NEPH) Projected to Post Earnings on Thursday

Nephros (NASDAQ:NEPH) will likely be announcing its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $4.4510 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Nephros Trading Up 3.6%

Shares of NEPH opened at $4.01 on Tuesday. Nephros has a 12-month low of $1.49 and a 12-month high of $6.42. The firm has a market capitalization of $42.63 million, a P/E ratio of 30.85 and a beta of 1.42. The firm has a 50-day moving average price of $4.31 and a 200 day moving average price of $4.65.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Nephros in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Hedge Funds Weigh In On Nephros

Several large investors have recently modified their holdings of the business. Kestra Advisory Services LLC acquired a new stake in shares of Nephros during the 4th quarter worth about $29,000. Heron Bay Capital Management acquired a new position in Nephros in the fourth quarter valued at about $66,000. Dimensional Fund Advisors LP purchased a new position in Nephros during the third quarter worth about $64,000. Citadel Advisors LLC boosted its stake in Nephros by 39.2% during the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after buying an additional 4,655 shares during the period. Finally, XTX Topco Ltd increased its position in shares of Nephros by 48.5% during the fourth quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after acquiring an additional 7,062 shares during the last quarter. Institutional investors and hedge funds own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.